146 related articles for article (PubMed ID: 18656274)
1. Effects of intracoronary compared to intravenous abciximab administration in patients undergoing transradial percutaneous coronary intervention: A sub-analysis of the EASY trial.
Bertrand OF; Rodés-Cabau J; Larose E; Nguyen CM; Déry JP; Proulx G; Roy L; Poirier P; Costerousse O; De Larochellière R
Int J Cardiol; 2009 Aug; 136(2):165-70. PubMed ID: 18656274
[TBL] [Abstract][Full Text] [Related]
2. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L
Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635
[TBL] [Abstract][Full Text] [Related]
3. Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study.
Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Gaudreault V; Proulx G; Barbeau G; Déry JP; Gleeton O; Manh-Nguyen C; Noël B; Roy L; Costerousse O; De Larochellière R;
Am J Cardiol; 2010 Jun; 105(11):1520-7. PubMed ID: 20494655
[TBL] [Abstract][Full Text] [Related]
4. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
Thiele H; Schindler K; Friedenberger J; Eitel I; Fürnau G; Grebe E; Erbs S; Linke A; Möbius-Winkler S; Kivelitz D; Schuler G
Circulation; 2008 Jul; 118(1):49-57. PubMed ID: 18559698
[TBL] [Abstract][Full Text] [Related]
5. Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial.
Iversen A; Abildgaard U; Galloe A; Hansen PR; Galatius S; Madsen JK; Engstroem T; Pedersen S; Jensen KS; Jensen JS
J Interv Cardiol; 2011 Apr; 24(2):105-11. PubMed ID: 21175845
[TBL] [Abstract][Full Text] [Related]
6. Aborted myocardial infarction in intracoronary compared with standard intravenous abciximab administration in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction.
Eitel I; Desch S; Schindler K; Fuernau G; Schuler G; Thiele H
Int J Cardiol; 2011 Nov; 153(1):21-5. PubMed ID: 20817283
[TBL] [Abstract][Full Text] [Related]
7. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation.
Bertrand OF; De Larochellière R; Rodés-Cabau J; Proulx G; Gleeton O; Nguyen CM; Déry JP; Barbeau G; Noël B; Larose E; Poirier P; Roy L;
Circulation; 2006 Dec; 114(24):2636-43. PubMed ID: 17145988
[TBL] [Abstract][Full Text] [Related]
8. Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention--effects on soluble CD40 ligand concentrations.
Dominguez-Rodriguez A; Abreu-Gonzalez P; Avanzas P; Bosa-Ojeda F; Samimi-Fard S; Marrero-Rodriguez F; Kaski JC
Atherosclerosis; 2009 Oct; 206(2):523-7. PubMed ID: 19380134
[TBL] [Abstract][Full Text] [Related]
9. Intracoronary compared to intravenous abciximab in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention reduces mortality, target vessel revascularization and reinfarction after 1 year.
Iversen AZ; Galatius S; Abildgaard U; Galloe A; Hansen PR; Pedersen S; Engstroem T; Jensen JS
Cardiology; 2011; 120(1):43-9. PubMed ID: 22122887
[TBL] [Abstract][Full Text] [Related]
10. One-year clinical outcome after abciximab bolus-only compared with abciximab bolus and 12-hour infusion in the Randomized EArly Discharge after Transradial Stenting of CoronarY Arteries (EASY) Study.
Bertrand OF; Rodés-Cabau J; Larose E; Nguyen CM; Roy L; Déry JP; Courtis J; Nault I; Poirier P; Costerousse O; De Larochellière R
Am Heart J; 2008 Jul; 156(1):135-40. PubMed ID: 18585508
[TBL] [Abstract][Full Text] [Related]
11. Intracoronary versus intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: 6-month effects on infarct size and left ventricular function. The randomised Leipzig Immediate PercutaneouS Coronary Intervention Abciximab i.v. versus i.c. in ST-Elevation Myocardial Infarction Trial (LIPSIAbciximab-STEMI).
Eitel I; Friedenberger J; Fuernau G; Dumjahn A; Desch S; Schuler G; Thiele H
Clin Res Cardiol; 2011 May; 100(5):425-32. PubMed ID: 21125288
[TBL] [Abstract][Full Text] [Related]
12. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials.
De Luca G; Verdoia M; Suryapranata H
Atherosclerosis; 2012 Jun; 222(2):426-33. PubMed ID: 22483166
[TBL] [Abstract][Full Text] [Related]
13. Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI.
Romagnoli E; Burzotta F; Trani C; Mazzari MA; Biondi-Zoccai GG; De Vita M; Giannico F; Niccoli G; Prati F; Rebuzzi AG; Mongiardo R; Crea F
Int J Cardiol; 2005 Dec; 105(3):250-5. PubMed ID: 16274764
[TBL] [Abstract][Full Text] [Related]
14. Economic impact of same-day home discharge after uncomplicated transradial percutaneous coronary intervention and bolus-only abciximab regimen.
Rinfret S; Kennedy WA; Lachaine J; Lemay A; Rodés-Cabau J; Cohen DJ; Costerousse O; Bertrand OF
JACC Cardiovasc Interv; 2010 Oct; 3(10):1011-9. PubMed ID: 20965458
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials.
Navarese EP; Kozinski M; Obonska K; Margheri M; Gurbel PA; Kubica J; De Luca G
Platelets; 2012; 23(4):274-81. PubMed ID: 21988317
[TBL] [Abstract][Full Text] [Related]
16. Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting.
Kakkar AK; Moustapha A; Hanley HG; Weiss M; Caldito G; Misra P; Reddy PC; Tandon N
Catheter Cardiovasc Interv; 2004 Jan; 61(1):31-4. PubMed ID: 14696156
[TBL] [Abstract][Full Text] [Related]
17. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty.
Wöhrle J; Grebe OC; Nusser T; Al-Khayer E; Schaible S; Kochs M; Hombach V; Höher M
Circulation; 2003 Apr; 107(14):1840-3. PubMed ID: 12682003
[TBL] [Abstract][Full Text] [Related]
18. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial.
Thiele H; Wöhrle J; Neuhaus P; Brosteanu O; Sick P; Prondzinsky R; Birkemeyer R; Wiemer M; Kerber S; Schuehlen H; Kleinertz K; Axthelm C; Zimmermann R; Rittger H; Braun-Dullaeus RC; Lauer B; Burckhardt W; Ferrari M; Bergmann MW; Hambrecht R; Schuler G;
Am Heart J; 2010 Apr; 159(4):547-54. PubMed ID: 20362711
[TBL] [Abstract][Full Text] [Related]
19. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
[TBL] [Abstract][Full Text] [Related]
20. ClearWayRX system to reduce intracoronary thrombus in patients with acute coronary syndromes according to optical coherence tomography after abciximab intracoronary local infusion trial (COCTAIL): study rationale and design.
Capodanno D; Prati F; Pawlowsky T; Ramazzotti V; Albertucci J; La Manna A; Robert G; Tamburino C
J Cardiovasc Med (Hagerstown); 2010 Feb; 11(2):130-6. PubMed ID: 19829141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
